New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org

ALBANY, New York, September 17, 2012 /PRNewswire/ --

Twease.org - New Report Added in Pharmaceutical Reports Database Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

The report provides an overview of the most exciting innovations in drug delivery technologies in major therapeutic areas oncology, vaccines, diabetes, rheumatology and respiratory diseases. Each chapter highlights emerging companies with technologies that have the potential to transform drug delivery in that specific therapeutic area. The report also explores the current environment in healthcare and the pharmaceutical industry, and examines drivers and challenges for the use of innovative drug delivery technologies.

To Browse Full Toc Visit: http://www.twease.org/report/innovations-in-drug-delivery-broad-based-proprietary-technology-platforms-to-address-delivery-efficiency-and-improve-patient-compliance.htm

Drug delivery technologies provide commercial opportunities for pharmaceutical companies by improving the chances of success for a drug development project. They enable the formulation of a promising molecule that might have poor solubility or require selective delivery to a particular tissue, such as the brain. Similarly, drug delivery technologies may enable companies to differentiate products within crowded therapeutic areas, facilitate life cycle management for existing drugs, and reposition existing drugs proprietary or generic in new indications where the needs of the patient population are different or, again, where more targeted delivery is required. Products that are reformulated with novel drug delivery systems do not meet the traditional criteria for innovative products in other words, products that include new active moieties. Nevertheless, GBI Researchs analysis shows that the commercial success of existing products that rely on innovative drug delivery technologies is clear, and these products make significant positive changes for patients.

Scope

  • Detailed analysis of the reasons for the industry to look closely at drug delivery technologies.
  • Exploration of the environment in healthcare and the pharmaceutical industry that is driving companies to invest in drug delivery.
  • Insight into collaborations between the largest pharmaceutical companies and smaller companies with innovative drug delivery technologies.
  • Detailed insight into innovation in drug delivery in key therapeutic areas: oncology, vaccines, diabetes, rheumatology and respiratory diseases.
  • Case studies of leading companies, their technologies and clinical data emerging from important drug development programs.

Related Reports:

Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market

Innovations in Drug Delivery

Healthcare, Regulatory and Reimbursement Landscape - Taiwan

China Synthesis Polypeptide Drug Industry

Pharmaceutical Pricing and Reimbursement - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making

7TM Pharma A/S - Product Pipeline Review - 2012

Adamis Pharmaceuticals Corporation - Product Pipeline Review - 2012

AVEO Pharmaceuticals, Inc. - Product Pipeline Review

Hepatitis C - Pipeline Review, H2 2012

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review

Gouty Arthritis (Gout) - Pipeline Review

Reasons to buy

  • Identify leading drug delivery companies. 
  • Learn about mergers, acquisitions and collaborations in drug delivery.
  • Develop strategies and priorities for investing in drug delivery technologies.
  • Understand the most important technologies and companies involved in developing new drug delivery technologies in key therapeutic areas.
  • Explore the needs of patients in each therapeutic area and the ways in which drug delivery technologies can be used to meet these within drug development pipelines.

About Us

Twease.org is the number one stop for all the latest reports, news and industry information related to pharmaceutical domain. Our database represents a collection which is updated on a daily basis and consists of all major pharmaceutical market research publishers.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
Email[email protected]
Visit: http://www.twease.org/ 
Buy SWOT: http://www.wpt9.com/ 
Blog: http://marketsindustryresearch.blogspot.fr/ 

SOURCE Twease.org

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.